← back to search

Arjun Nair

Neurological Surgery · US
Area of research
Pulmonary and Respiratory Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Lung Cancer Diagnosis and Treatment, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Radiomics and Machine Learning in Medical Imaging, and Chronic Obstructive Pulmonary Disease (COPD) Research.
h-index
47
citations
9,386
works
288
NIH funding
primary concept
Medicine
email

Recent publications

ESR Essentials: lung cancer screening with low-dose CT-practice recommendations by the European Society of Thoracic Imaging.
2026cited by 1position: contributordoi
Upstaging of screen-detected lung cancers during diagnostic assessment.
2026cited by 1position: contributordoi
Expanded detection of early fibrotic phenotypes using lobar traction bronchiolectasis in lung cancer screening.
2026cited by 0position: contributordoi
Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
2026cited by 0position: contributordoi
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.
2025cited by 49position: contributordoi
Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
2025cited by 28position: contributordoi
Subclonal immune evasion in non-small cell lung cancer.
2025cited by 12position: contributordoi
DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution.
2025cited by 6position: contributordoi
ImmuneLENS characterizes systemic immune dysregulation in aging and cancer.
2025cited by 6position: contributordoi
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma.
2025cited by 6position: contributordoi
Improving uptake of lung cancer screening: an observational study on the impact of timed appointments and reminders.
2025cited by 4position: contributordoi
Quality assurance in lung cancer screening.
2025cited by 2position: contributordoi
Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening.
2025cited by 2position: contributordoi
Incidence rate and malignancy risk in new nodules in a lung cancer screening programme.
2025cited by 1position: contributordoi
Protocol for a systematic review and individual participant data meta-analysis for risk factors for lung cancer in individuals with lung nodules identified by low-dose CT screening.
2025cited by 1position: contributordoi
Impact of Low-Dose Computed Tomography Findings on Cigarette Smoking Cessation Among High-Risk Adults Participating in Lung Cancer Screening.
2025cited by 0position: contributordoi
Differentiating clinically important interstitial lung abnormalities in lung cancer screening.
2025cited by 0position: contributordoi
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
2024cited by 41position: contributordoi
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.
2024cited by 33position: contributordoi
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma.
2024cited by 27position: contributordoi
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models.
2024cited by 19position: contributordoi
Mortality surrogates in combined pulmonary fibrosis and emphysema.
2024cited by 15position: contributordoi
Enhancing cancer prediction in challenging screen-detected incident lung nodules using time-series deep learning.
2024cited by 7position: contributordoi
Predicting histopathological features of aggressiveness in lung cancer using CT radiomics: a systematic review.
2024cited by 4position: contributordoi
Determining the impact of an artificial intelligence tool on the management of pulmonary nodules detected incidentally on CT (DOLCE) study protocol: a prospective, non-interventional multicentre UK study.
2024cited by 4position: contributordoi
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.
2024cited by 3position: contributordoi
Stage at Diagnosis Following Delay to Interval Scans for Indeterminate Nodules in Lung Cancer Screening: An Observational Study Examining the Outcomes of CHEST Expert Panel Recommendations.
2024cited by 1position: contributordoi
Temporal evolution of chest radiographic appearances in COVID-19 with clinicoradiological associations: a multicentre United Kingdom resident-led study.
2024cited by 0position: contributordoi
Lung adenocarcinoma promotion by air pollutants.
2023cited by 521position: contributordoi
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
2023cited by 260position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Sam M. Janes · Royal London Hospital17 papers (2019–2026)David Baldwin · University of Nottingham12 papers (2015–2025)Neal Navani · University College Hospital8 papers (2019–2026) · 7 papers (2022–2026) · 5 papers (2020–2026)James L. Reading · The London College4 papers (2024–2025)Mark G Jones · Imperial College London4 papers (2021–2026)Mamta Ruparel · BMJ Publishing Group4 papers (2019–2020)John R Hurst · Express Medicals (United Kingdom)4 papers (2020–2023)Joanna C Porter · University of Sheffield4 papers (2021–2024)Joseph Jacob · Elsevier, Inc.4 papers (2023–2026)Amyn Bhamani · University College London4 papers (2023–2026) · 4 papers (2022–2026) · 4 papers (2020–2025)John K. Field · Tianjin Medical University Cancer Institute and Hospital4 papers (2019–2025)Charles Swanton · Cancer Evolution and Genome Instability Laboratory4 papers (2024–2025)Fiona Blackhall · University of Manchester3 papers (2024–2025)Helen Hall · University College London3 papers (2022–2026)Caroline Dive · University College London3 papers (2024–2025) · 3 papers (2024–2025)